key: cord-0915690-e9w4n7is
authors: Sbeih, Firas; Gutierrez, Jorge; Saieed, George; Chaaban, Mohamad R.
title: Chronic rhinosinusitis is associated with increased risk of COVID-19 hospitalization()
date: 2022-04-09
journal: Am J Otolaryngol
DOI: 10.1016/j.amjoto.2022.103469
sha: 59258f44251caad225721f45ae1c28095033a6f7
doc_id: 915690
cord_uid: e9w4n7is

OBJECTIVE: The rationale of the study was to examine the association between chronic rhinosinusitis (CRS) and COVID-19 hospitalization. STUDY DESIGN: Retrospective cohort study. SETTING: Cleveland Clinic hospital inpatient and outpatient. METHODS: A retrospective chart review of patients that were tested for COVID-19 at Cleveland Clinic. The study took place between March 8, 2020 and May 15, 2020. RESULTS: From a total of 23,282 Patients that underwent SARS-CoV-2 testing, 996 COVID-19 negative and 998 COVID-19 positive patients were included in the analysis. COVID-19 positive patients with chronic rhinosinusitis (CRS) were at higher risk for hospitalization compared to patients without CRS (39.2% vs 25.7%, p = 0.0486). There was no significant difference between the two groups in relation to ICU admission, mechanical ventilation, and death, After adjustment for covariates, our multivariate analysis showed that patients with chronic rhinosinusitis (CRS) were approximately 3.46 (OR = 3.19, 95% CI (1.12–10.68)) times more likely to be hospitalized compared to patients that have no CRS. CONCLUSION: Our results demonstrated that patients with chronic rhinosinusitis are associated with higher risk of COVID-19 hospitalization, albeit no increased risk of mortality.

Since the declaration of the coronavirus disease 2019 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in March 2020, the disease has spread rapidly throughout the world. 1 COVID-19 has a highly variable presentation from asymptomatic disease to severe acute respiratory distress and death. SARS-CoV-2 is a contagious virulent organism with an incubation period of 2 to 14 days with asymptomatic patients capable of transmitting the infection. The nasal and oral cavities are believed to be the most common portals of entry for the virus prior to its propagation into the lungs where the major comorbidities of the virus arise. Early reports regarding symptoms from China were mostly related to cough, fever, and fatigue, with symptoms of upper respiratory symptoms such as rhinorrhea, sore throat, and nasal congestion reported as very uncommon. [2] [3] [4] [5] [6] Early systematic reviews also reported symptoms of fever in 83.3%, cough 60.3%, and fatigue in 38% with no reports on impaired sense of smell or taste in these studies. [6] [7] It was not until April 23 rd 2020 that the CDC (Centers for Disease Control and Prevention) has updated the symptoms to include -new loss of taste or smell‖ to the full list of COVID-19 symptoms. 8 Impaired sense of smell has been one of the early identified symptoms of COVID-19 as has been reported in multiple countries across the globe. There a wide variation in the reported loss of sense of smell with reported incidence as low as 5.1% and as large as 85.6%. 33, 34 This symptom is more commonly reported in mild to moderate COVID-19 and much less in severe In addition to the variable presentation of patients infected with COVID-19, one of the most important and puzzling issues is related to the ability to identify high risk patients that further go on and develop severe to critical COVID-19 requiring hospitalization, intensive care unit (ICU) admission, and mechanical ventilation. Determining inter-individual variation in disease severity has several implications including determining high risk patients and vaccine allocation. There are several known risk factors that have been linked to severe COVID-19 including advanced age and several comorbidities including chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, and obesity. [35] [36] Additionally, COPD was also found to be associated with increased health care J o u r n a l P r e -p r o o f Journal Pre-proof Data was collected on all patients that were tested for COVID-19 at CCF from March 8, 2020 until May 15, 2020. The registry started collecting data on symptomatic patients starting March 8,2020.

After April 15 th 2020, the registry stopped collecting data on COVID-19 negative patients. We excluded patients younger than 18 years old. For the analyses, we randomly collected patients from a total of 23,282 patients to include 1,000 COVID-19 positive patients, and 1,000 COVID-19 negative patients. A random number was assigned to each patient in Excel using the RAND function. Rows were then sorted in ascending order of the number previously generated, and the first 1,000 patients were selected for inclusion. This process was repeated for adults who tested negative for COVID-19. Data collected included demographics, COVID-19 testing results, symptoms, comorbidities, health care utilization, imaging, medications, ICU admission, mechanical ventilation, and mortality.

Descriptive statistics were presented as numbers and percentage for categorical variables with mean and standard deviation for continuous variables. Chi-square test was applied for group comparisons on categorical data, and the Fisher exact test was applied for data with an expected value < 5. Group comparisons on continuous data, the Wilcoxon 2-sample test was used. Multivariate logistic regression models were applied for patient symptoms, demographic characteristics, and comorbidities that were significant from our bivariate analysis. Statistical analysis was performed using SAS JMP Pro p<0.0001). The COVID-19 negative group had significantly more smokers and comorbidities such as asthma, COPD, coronary artery disease, and heart failure.

Compared to the COVID-19 negative group, the COVID- 19 Table 2 . There was no statistically significant difference in age and race between the COVID-19 positive patients with and without CRS. In terms of symptoms, COVID-19 positive patients with CRS experienced more rhinorrhea (25.5% vs 14.1%, p=0.041) compared to patients without CRS. The difference in other symptoms between the COVID-19 positive patients with CRS and without CRS did not reach statistical significance. COVID-19 positive patients with CRS were at higher risk for hospitalization compared to patients without CRS (38.46% vs 25.82%, p=0.036). However, there was no significant difference between the two groups in relation to ICU admission, mechanical ventilation, and death (table 2).

The demographic and clinical characteristics of COVID-19 positive patients with and without impaired sense of smell are included in Table 3 . The group that experienced impaired sense of smell J o u r n a l P r e -p r o o f Journal Pre-proof was significantly younger than the group that did not experience impaired sense of smell (45.0 +/-1.07 vs 56.8 +/-0.68, p<0.0001). There was no significant difference between the two groups in race. In terms of symptoms, patients that had impaired sense of smell reported significantly more upper respiratory symptoms of nasal congestion, rhinorrhea, and loss of taste (p<0.0001). In addition, this subset of patients with impaired sense of smell had significantly lower comorbidities including hypertension, heart failure, and coronary artery disease (p<0.0001). COVID-19 positive patients with impaired sense of smell were significantly less hospitalized (13.97% vs 29.29%, p<0.0001), and there were no deaths in this group (0.00% vs 5.49%, p=0.0223).

Regarding need for hospitalization in the COVID-19 positive group ( 

Using our CCF COVID-19 registry, we found that chronic rhinosinusitis (CRS) patients have an increased risk for hospitalization when compared to patients without CRS. Since the nasal and oral cavities are gateways for entry of the virus into the body, it is not surprising that upper airway pathologies may play a role in COVID-19 clinical outcomes. There are seven coronaviruses that cause infections in humans apart from SARS-CoV-2. 44 Research has shown that the primary site of entry of coronaviruses depend on the type, with MERS-CoV infecting type II pneumocytes, SARS-CoV involving the lungs and SARS-CoV-2 infecting the nose and throat. 45 It is thought that goblet and ciliated cells are the targets that the virus infects 46 with nasal epithelial cells displaying the highest expression for ACE-2 receptors in the respiratory tree. The mechanism of entry into the host is through the interaction between its spike protein S1 and the host angiotensin-converting enzyme 2 (ACE2) receptor. 47 Transmembrane protease serine 2 (TMPRSS2) which is expressed in the host cells also plays a pivotal role in pathogenesis as it cleaves the viral S glycoprotein causing activation of viral particles. 48 In addition to nasal epithelial cells, recent studies have shown that ACE2 and TMPRSS2 are expressed by sustentacular and basal cells of the olfactory epithelium and are not expressed by olfactory sensory neurons 49 suggesting that olfactory impairment is related to the damage of the supporting cells rather than neurons.

CRS is among the most common chronic diseases in the world, affecting about 15% of the U.S. population. 50 The formal criteria for diagnosis includes the presence of 2 or more of the following cardinal symptoms for 12 weeks: nasal obstruction, nasal discharge, facial pressure or hyposmia; and objective evidence of inflammation/purulence from the paranasal sinuses on computed tomography (CT) or nasal endoscopy. 51 All patients diagnosed with CRS in this study were diagnosed by an otolaryngologist adhering to the aforementioned diagnostic criteria. Histologically, CRS differs based on whether the inflammation is eosinophilic versus neutrophilic. 52 In terms of symptoms, COVID-19 54 Patients with chronic sinusitis without nasal polyps were noted to be at increased risk. 54 Our observed increased risk of COVID-19 hospitalization could be explained by the variation in receptor densities in the nasal epithelium of CRS patients or the use of steroids as part of the standard treatment of this disease. The first line treatment of CRS is intranasal corticosteroids; however, it is unlikely that the use of intranasal corticosteroids affected the outcome of our COVID-19 patients. In a study on COVID-19 positive patients with COPD, inhaled corticosteroid use was found to be protective against hospitalization of COVID-19 infections. 36 Our observed worse outcomes in CRS patients are more likely to be explained by potential differences in ACE2 receptor densities in CRS patients. Several studies have found that patients with non-eosinophilic CRS had increased ACE2 and TMPRSS2 expression compared to eosinophilic CRS patients. 55, 56 Another study looked at the effect of eosinophilic vs neutrophilic inflammatory histopathological profile on COVID-19 in asthmatics. Patients with the neutrophilic asthma phenotype were found to be at higher risk for COVID-19 infection compared to the eosinophilic counterpart. 57 Due to the nature of our study, we were not able to Our study has several limitations. First, it was conducted at the beginning of the COVID-19 pandemic in the U.S. There was less awareness for testing at that time particularly among the younger patients which may present milder forms of COVD-19. Hence, we believe that impaired sense of smell is underreported in our study. Second, we were not able to divide CRS into eosinophilic vs neutrophilic endotypes. Third, our study was retrospective in nature and we were not able to collect data on the use of intranasal steroids given their over the counter use. Fourth, our study included Cleveland Clinic patients in Northeast Ohio and Southeast Florida population, which limits the generalizability of our results.

Chronic rhinosinusitis is associated with increased risk of hospitalization due to COVID-19. Future studies are needed to examine the mechanistic bases and examine the relationship in a prospective fashion.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

TISSUES 2.0: an integrative web resource on mammalian tissue expression

Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specifc expression of mediators of SARS-CoV-2 viral entry and highlights infammatory programs in putative target cells

The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain

The scRNA-seq expression profling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to COVID-19 infection

Multiple organ infection and the pathogenesis of SARS

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Retrospective analysis of smell and taste disturbances associated with dermatological medications reported to the United States Food and Drug Administration and relevance to COVID-19 infections

Taste and smell dysfunction in COVID-19 patients

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based casecontrol study

Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched case-control study

Subjective changes in smell and taste during the COVID-19 pandemic: a national survey-preliminary results

Otolaryngol Head Neck Surg

A new symptom of COVID-19: loss of taste and smell

COVID-19 and anosmia in Tehran

Early recovery following new onset anosmia during the COVID-19 pandemic: an observational cohort study

Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19

Features of anosmia in COVID-19

Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection

Anosmia as a presenting symptom of SARS-CoV-2 infection in healthcare workers: a systematic review of the literature, case series, and recommendations for clinical assessment and management

Prevalence and duration of acute loss of smell or taste in COVID-19 patients

Aggregate prevalence of chemosensory and sinonasal dysfunction in SARSCoV-2 and related coronaviruses

Otolaryngol Head Neck Surg

Subjective neurological symptoms frequently occur in patients with SARSCoV2 infection

Analysis of imported cases of COVID-19 in Taiwan: a nationwide study

Neurologic manifestations of hospitalized patients with coronavirus disease

Real-time tracking of self-reported symptoms to predict potential COVID-19

COVID-19 outbreak in Iraqi Kurdistan: the first report characterizing epidemiological, clinical, laboratory, and radiological findings of the disease

Smell dysfunction: a biomarker for COVID-19

Smell and taste symptom-based predictive model for COVID-19 diagnosis

Olfactory dysfunction and sinonasal symptomatology in COVID-19: prevalence, severity, timing, and associated characteristics

Otolaryngol Head Neck Surg

The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis

Anosmia and ageusia: common findings in COVID-19 patients

Clinical features of Covid-19

Self-reported olfactory loss associates with outpatient clinical course in Covid-19

Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Olfactory and gustatory dysfunctions as a clinical presentation of mildto-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry

Home monitoring for COVID-19

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state

Covid19 in critically ill patients in the Seattle region -case series

Clinical characteristics of coronavirus disease 2019 in China

The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the chinese center for disease control and prevention

Extracting and utilizing electronic health data from fpic for research

Nervous system involvement after infection with COVID-19 and other coronaviruses

Position paper on olfactory dysfunction

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancerFuture

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

An Empirical Study of Chronic Diseases in the United States: A Visual Analytics Approach to Public Health

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. International forum of allergy & rhinology

Pathogenesis of eosinophilic chronic rhinosinusitis

The characterization of chronic rhinosinusitis in hospitalized patients with COVID-19

Estimating COVID-19 Infection and Severity Risks in Patients with Chronic Rhinosinusitis: A Korean Nationwide Cohort Study

Are patients with chronic rhinosinusitis with nasal polyps at a decreased risk of COVID-19 infection? Int Forum Allergy Rhinol

Viral stimulation modulates endotype-related ACE2 expression in eosinophilic chronic rhinosinusitis

Implications of preexisting asthma on COVID-19 pathogenesis